SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction.
"We are very pleased to participate in the annual meeting of the American Society for Reproductive Medicine," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "Endometriosis is a leading cause of infertility in women and this scientific meeting brings together the world's thought leaders in obstetrics, gynecology, and endocrinology to discuss the latest advances in the field. We look forward to sharing our elagolix clinical data at this meeting."
An abstract from the Daisy Petal clinical study of elagolix for the treatment of endometriosis-associated pain will be presented at the 67th Annual Meeting of the American Society for Reproductive Medicine on Tuesday, October 18, 2011 at 4:15 pm during the abstract sessions. Bruce Carr, M.D. the Paul C. MacDonald Distinguished Chair in Obstetrics and Gynecology at University of Texas Southwestern Medical School will present "A Novel Oral GnRH Antagonist, Elagolix, is Effective For Reducing Endometriosis-Associated Pelvic Pain: Results of a 24-Week Randomized Study."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2010 and report on Form 10-Q for the quarter ended June 30, 2011. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.
|SOURCE Neurocrine Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved